Background & Objective: Nasopharyngeal carcinoma(NPC) is an EB virus (EBV) related cancer. Recently, it was reported that EBV DNA can be detected in NPC patients' plasma or serum. This study was designed to investigate the correlation between the kinetics of plasma EBV DNA levels and clinical response during concomitant chemo-radiotherapy in the locally advanced nasopharyngeal carcinoma patients.
Methods: Blood samples from 20 patients were collected weekly during chemo-radiotherapy(7 times, in total). The first blood sample was collected before treatment. The content of EBV DNA in the samples were detected by using fluorescent quantitative PCR method in the PE Appliance Biosystems 7700 Sequence Detector.
Results: Before treatment, plasma EBV DNA was detectable in the plasma of 90% (18/20) NPC patients. The median concentration was 150,000(copies/ml). Two patients' plasma EBV DNA could not be detected during the whole course of treatment. Among 18 EBV DNA-positive patients, 3 patients had a continuously high EBV DNA and clinical examination after treatment indicated that they had residual tumors. Seven patients'plasma EBV DNA levels had a rapid decline to be undetectable. Eight patients' plasma EBV DNA levels got a slow decline, but the EBV DNA could not be detected at the end of therapy as well. Clinical examination revealed that all of these 15 patients had complete tumor regression.
Conclusion: Kinetic analysis of plasma EBV DNA during treatment may be a useful tool to monitor the treatment response in NPC patients. Further investigation is warranted.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Risk stratification based on changes in the standard maximal uptake value on PET/CT and the plasma Epstein‒Barr virus (EBV) DNA status after two cycles of chemotherapy for extranodal NK-/T-cell lymphoma.
Ann Hematol
December 2024
Department of Medical Oncology, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Although different types of prognostic indices have been applied in extranodal NK-/T-cell lymphoma (ENKTL), they are based mainly on clinical characteristics before treatment. Moreover, these methods lack early assessment and tumor metabolic parameters. It remains unclear whether changes in the plasma Epstein-Barr virus DNA (EBVDNA) status and SUVmax after two cycles of chemotherapy may predict disease prognosis.
View Article and Find Full Text PDFHerpesviruses, including the oncogenic Epstein-Barr Virus (EBV), must bypass host DNA sensing mechanisms to establish infection. The first viral latency protein expressed, EBNA-LP, is essential for transformation of naïve B cells, yet its role in evading host defenses remains unclear. Using single-cell RNA sequencing of EBNA-LP-Knockout (LPKO)-infected B cells, we reveal an antiviral response landscape implicating the 'speckled proteins' as key restriction factors countered by EBNA-LP.
View Article and Find Full Text PDFSystemic immune inflammation index combined with Epstein-Barr virus DNA for predicting the prognosis of nasopharyngeal carcinoma: A retrospective study.
Am J Otolaryngol
December 2024
Department of Otolaryngology, Far Eastern Memorial Hospital, New Taipei, Taiwan; Head and Neck Cancer Surveillance & Research Group, Far Eastern Memorial Hospital, New Taipei, Taiwan; Department of Electrical Engineering, Yuan Ze University, Taoyuan, Taiwan. Electronic address:
Background: Cancer has consistently been the leading cause of death worldwide, with head and neck cancer (HNC) being one of the top ten causes of cancer-related death. Nasopharyngeal carcinoma (NPC), in particular, is a cancer that is unique to East Asia. Numerous studies have shown that the Epstein-Barr virus (EBV) DNA load and the systemic immune inflammation (SII) index can serve as prognostic indicators for NPC patients.
View Article and Find Full Text PDFEfficacy of local-regional radiotherapy in de novo metastatic nasopharyngeal carcinoma patients receiving chemo-immunotherapy: A multicenter, propensity score matching study.
Radiother Oncol
December 2024
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 510060, Guangzhou, China. Electronic address:
Background: To evaluate the efficacy of local-regional radiotherapy (LRRT) in de novo metastatic nasopharyngeal carcinoma (dm NPC) patients receiving chemo-immunotherapy as first-line treatment and select the beneficiaries from LRRT.
Methods And Materials: M1-NPC patients receiving platinum-based chemo-immunotherapy with or without LRRT from four centers were included in this study. The propensity score matching (PSM) analysis was employed to balance the baseline characteristics between the LRRT and non-LRRT groups.
Epstein-Barr virus-associated lymphoproliferative disease during remission after induction therapy with dasatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a case report.
Ann Hematol
December 2024
Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Dasatinib, a second-generation tyrosine kinase inhibitor, has been reported to have immunomodulatory effects. Epstein-Barr virus (EBV)-associated lymphoproliferative disorders (EBV-LPD) occur in immunocompromised patients, such as those receiving methotrexate or other immunosuppressive drugs or after allogenic transplantation. EBV-LPD is also reported to be a rare side effect in patients receiving long-term dasatinib or imatinib.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!